Los Angeles Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Los Angeles Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-15,793	Closed	-$595K	–	1747
2021 Q1	$595K	Buy	+15,793	New	+$394K	﹤0.01%	1140
2018 Q3	–	Sell	-48,445	Closed	-$766K	–	1525
2018 Q2	$766K	Buy	48,445 +17,270	+55%	+$301K	﹤0.01%	1007
2018 Q1	$536K	Buy	+31,175	New	+$608K	﹤0.01%	1013
2017 Q4	–	Sell	-48,136	Closed	-$1.97M	–	1425
2017 Q3	$1.97M	Sell	48,136 -5,040	-9%	-$158K	0.01%	622
2017 Q2	$1.6M	Buy	53,176 +36,780	+224%	+$1.15M	0.01%	658
2017 Q1	$593K	Buy	+16,396	New	+$723K	﹤0.01%	849

Los Angeles Capital Management's FPRX Position: Q2 2021 in Review

Los Angeles Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 15,793 shares — an estimated $595K sold.

Los Angeles Capital Management first reported a position in FPRX in Q1 2017 and held it in 6 quarters. The position peaked at $1.97M in Q3 2017. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

Los Angeles Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Los Angeles Capital Management sold 15,793 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $595K.
Los Angeles Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2017 and held it in 6 quarters.
Los Angeles Capital Management's Five Prime Therapeutics, Inc. position peaked at $1.97M in Q3 2017.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Los Angeles Capital Management's 13F filing for Q2 2021, filed 5 Aug 2021.